In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells. (2020). Brazilian Journal of Pharmaceutical Sciences, 56, e18254. https://doi.org/10.1590/s2175-97902019000318254